Overview

Study to Evaluate D2 Receptor Occupancy Following Single Intravenous Administration of ATI-9242

Status:
Completed
Trial end date:
2016-11-08
Target enrollment:
Participant gender:
Summary
This study involves evaluating the occupancy of ATI-9242 at steady state at three different dose levels on D2 receptors in the brain using [18F] Fallypride PET in up to three cohorts of subjects.
Phase:
Phase 1
Details
Lead Sponsor:
Braeburn Pharmaceuticals
Treatments:
Fallypride